| Primary hypogonadism
Jatenzo vs Natesto
Side-by-side clinical, coverage, and cost comparison for primary hypogonadism.Deep comparison between: Jatenzo vs Natesto with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNatesto has a higher rate of injection site reactions vs Jatenzo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Natesto but not Jatenzo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jatenzo
Natesto
At A Glance
Oral
Twice daily
Androgen
Intranasal
Three times daily
Androgen
Indications
- Primary hypogonadism
- Hypogonadotropic hypogonadism
- Primary hypogonadism
- Hypogonadotropic hypogonadism
Dosing
Primary hypogonadism, Hypogonadotropic hypogonadism Starting dose 237 mg orally twice daily (morning and evening) with food; dose adjusted between 158 mg and 396 mg twice daily based on serum testosterone concentration measured 6 hours after the morning dose.
Primary hypogonadism, Hypogonadotropic hypogonadism 11 mg (2 pump actuations, 1 per nostril) administered intranasally three times daily (morning, afternoon, and evening, 6-8 hours apart) for a total daily dose of 33 mg; discontinue if total testosterone consistently exceeds 1050 ng/dL.
Contraindications
- Carcinoma of the breast or known or suspected carcinoma of the prostate
- Pregnancy
- Known hypersensitivity to JATENZO or any of its ingredients
- Carcinoma of the breast or known or suspected carcinoma of the prostate
- Women who are or may become pregnant
- Women who are breast-feeding
Adverse Reactions
Most common (>=2%) Headache, hematocrit increased, hypertension, HDL decreased, nausea
Postmarketing Myocardial infarction, stroke, venous thromboembolism
Most common (>=3%) PSA increased, headache, rhinorrhea, epistaxis, nasal discomfort, nasopharyngitis, bronchitis, upper respiratory tract infection, sinusitis, nasal scab
Postmarketing Myocardial infarction, stroke, venous thromboembolism
Pharmacology
Testosterone undecanoate is a prodrug ester of testosterone; after oral absorption via intestinal lymphatics, endogenous esterases cleave the ester bond to release active testosterone, which binds androgen receptors to support normal male sexual development and maintenance of secondary sex characteristics.
Testosterone is an endogenous androgen responsible for the normal growth and development of male sex organs and maintenance of secondary sex characteristics; Natesto delivers physiologic amounts of testosterone intranasally to restore deficient endogenous testosterone concentrations in hypogonadal men.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jatenzo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (10/12)
Natesto
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Jatenzo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Natesto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Jatenzo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Natesto
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jatenzo.
No savings programs available for Natesto.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JatenzoView full Jatenzo profile
NatestoView full Natesto profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.